Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

LaTorre: I think that the first thing that I would want to do is thank our investors for their support and assure them that we're making significant progress in developing our breath analyzer. The goal is to finally make point-of-care breath analysis a reality and to give them a great return on their investment. What we're trying to accomplish is to develop a tool that can be used to detect multiple disease states by using the same device, which opens the door for its use on millions of patients with many different disease types. So, there is an enormous addressable market and significant revenue opportunities in our future.

We will also be working in the field of infectious diseases as it relates to public health and try to reduce the overuse of antibiotics through differentiating between bacterial and viral infections like we're doing in our Vancouver clinical study on the NaNose. We're also working with microbiologists and epidemiologists to see if there is a potential to help stop the spread of infectious diseases at our borders that are a significant issue to the US and beyond. So, I believe that our future is very bright. I think the technology that we're developing will have enormous clinical applications and will really deliver on the promise of breath analysis for clinical use.

www.equities.com/news/breathtecs-handheld-analysis-device-getting-within-reach-ceo-guy-latorre

GUY LATORRE: THE INSIDE MAN



/////AMG